This Antibody was verified by Cell Treatment to ensure that the antibody binds to the antigen stated. View Details
PA3-030A detects inducible nitric oxide synthase (iNOS) from human and mouse tissues. This antibody does not detect endothelial NOS (eNOS) or brain NOS (bNOS).
PA3-030A has been successfully used in Western blot and immunohistochemistry (paraffin and frozen) procedures. By Western blot, this antibody detects an ~130 kDa protein representing iNOS in induced RAW 264.7 cell extracts.
The PA3-030A immunogen is a synthetic peptide corresponding to residues C K(1131) K G S A L E E P K A T R L(1144) of mouse macrophage NOS.
PA3-030A can be used with blocking peptide PEP-008.
Antibodies to this protein (and modification) were previously sold as part of a Thermo Scientific Cellomics High Content Screening Kit. This replacement antibody is now recommended for researchers who need an antibody for high content cell based assays. It has been thoroughly tested and validated for cellular immunofluorescence (IF) applications. Further optimization including the selection of the most appropriate fluorescent Dylight conjugated secondary antibody may have to be performed for your high content assay.
Nitric oxide (NO) is an inorganic, gaseous free radical that carries a variety of messages between cells. Vasorelaxation, neurotransmission and cytotoxicity can all be potentiated through cellular response to NO. NO production is mediated by members of the nitric oxide synthase (NOS) family. iNOS is expressed in liver and inducible by a combination of lipopolysaccharide and certain cytokines. NOS catalyzes the oxidization of L-arginine to produce L-citrulline and NO. Two constitutive isoforms, brain or neuronal NOS (b or nNOS, type I) and endothelial cell NOS (eNOS, type III), and one inducible isoform (iNOS, type II), have been cloned. All NOS isoforms contain calmodulin, nicotinamide adenine dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), and flavin mononucleotide (FMN) binding domains. iNOS is found in a variety of cell types including macrophages, hepatocytes, synoviocytes, and smooth muscle cells. Cytokines such as interferon-gamma (IFN), tumor necrosis factor (TNF), interleukin-1 and -2, and lipopolysaccarides (LPS) cause an increase in iNOS mRNA, protein, and activity levels. Protein kinase C-stimulating agents exhibit the same effect on iNOS activity. After cytokine induction, iNOS exhibits a delayed activity response which is then followed by a significant increase in NO production over a long period of time. Three related iNOS pseudogenes are located within the Smith-Magenis syndrome region on chromosome 17. Diseases associated with iNOS dysfunction include achalasia and impotence.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: HEP-NOS; Hepatocyte NOS; Inducible Nitric Oxide Synthase; Inducible NO synthase; Inducible NOS; MAC-NOS; Macrophage NOS; nitric oxide synthase 2, inducible; nitric oxide synthase 2, inducible, macrophage; nitric oxide synthase 2A (inducible, hepatocytes); Nitric oxide synthase, inducible; nitric oxide synthase, macrophage; NOS Type II; NOS, type II; Peptidyl-cysteine S-nitrosylase NOS2
Gene Aliases: HEP-NOS; i-NOS; INOS; Inosl; NOS; Nos-2; NOS-II; NOS2; NOS2A